 Home > Active Ingredient News > Drugs Articles > National centralized drug procurement inventory-dare to call the market a new day

National centralized drug procurement inventory-dare to call the market a new day

 Last Update: 2021-03-24
 Source: Internet
 Author: User

Tags

80 20 distributors

colorado pharmaceutical companies

1 2 epoxypentane

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> In November 2018, the "Documents for Centralized Procurement of Medicines in 4+7 Cities" was released.
Since then, the country has organized mass procurement.
As of February 3 this year, the national centralized procurement has carried out four rounds and five batches, which has had a greater impact on the market.
In the past two years, the rules and policies of centralized procurement have been gradually improved, the interval between rounds has been shortened, and the frequency has stabilized at two rounds a year, and has gradually become normalized.
Based on the policies and the Rubik's Cube database, the Rubik's Cube consulting team counted the trends and characteristics of these four rounds and five batches of collective procurement.

In November 2018, the "Documents for Centralized Procurement of Medicines in 4+7 Cities" was released.
Since then, the country has organized mass procurement.
As of February 3 this year, the national centralized procurement has carried out four rounds and five batches, which has had a greater impact on the market.
In the past two years, the rules and policies of centralized procurement have been gradually improved, the interval between rounds has been shortened, and the frequency has stabilized at two rounds a year, and has gradually become normalized.
Based on the policies and the Rubik's Cube database, the Rubik's Cube consulting team counted the trends and characteristics of these four rounds and five batches of collective procurement.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> 1.

The rules are gradually improved, and supporting policies are issued accordingly

1.
The rules are gradually improved and supporting policies are issued accordingly.
1.
The rules are gradually improved and the supporting policies are issued accordingly.

From the perspective of the rules, from 4+7 to the fourth round, the rules are gradually mature and perfect.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> In addition to the rules of centralized procurement itself, related supporting policies have also tended to be improved.

For example, during the third round of centralized procurement, the policy on the retention of medical insurance fund balances was released to encourage medical institutions to use centralized procurement winning bids and reasonably report the amount.
During the fourth round of centralized procurement, "Document 2" was released, officially normalizing and policyizing centralized procurement, and it was announced that centralized procurement of biological medicines and Chinese patent medicines will also be carried out in the future.

In addition to the rules of centralized procurement itself, related supporting policies have also tended to be improved.
For example, during the third round of centralized procurement, the policy on the retention of medical insurance fund balances was released to encourage medical institutions to use centralized procurement winning bids and reasonably report the amount.

2.
The rate of price decline increased round by round to promote the conservation of medical insurance funds.

The average price drop in the four rounds of centralized procurement increased from 4+7 to 51% to 75% in the fourth round of bid opening, with a median of 77%.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;white-space:normal;background-color:#FFFFFF;line-height:1.

5em;box-sizing:border-box ;overflow-wrap:break-word ;'>3.
Varieties and dosage forms are gradually enriched, and various disease fields are gradually being eaten away by collections3.
Varieties and formulations are gradually enriched, and various disease areas are gradually being eaten by collections.
3.

From the perspective of varieties and dosage forms, oral regular-release dosage forms have always been the mainstream of centralized procurement, which has nothing to do with the maturity of the consistency evaluation of the dosage form, and the number of consistency evaluations is an important consideration for the selection of centralized procurement varieties.
At the same time, we have seen that from 4+7/ to the fourth round, more and more dosage forms have been adopted.
In the second round, sustained and controlled release dosage forms and chewable tablets were newly included, and in the third round, granules, granules, and chewable tablets were newly included.
Orally disintegrating tablets, eye drops and oral solutions, inhalers were included for the first time in the fourth round.
In addition, the number of injection products accepted in the collection has gradually increased.
A total of 8 injection products have been included in this round.
Starting from the third round, the agreed procurement volume calculation ratio and procurement cycle of injection products are less than other formulations of the same number of selected manufacturers.
This is also the performance that the state encourages the consistency evaluation of injections.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> From the perspective of the disease field of the varieties, the four-round centralized collection varieties are mainly distributed in disease drugs such as neuropsychiatric drugs, anti-infective drugs, and lipid-lowering drugs.
Among them, lipid-lowering drugs are representatives of the "severe disaster areas" covered by centralized procurement.
In 4+7, the heavyweight lipid-lowering drugs atorvastatin and rosuvastatin were included in the centralized procurement catalog.
The second and third rounds Among them, simvastatin and pitavastatin have also become centralized collections.
So far, all the major varieties of lipid-lowering drugs have been included in the national collection, and the fourth round did not include lipid-lowering drugs.
In the future, more drugs will continue the fate of lipid-lowering drugs and will gradually be covered by centralized procurement.

From the perspective of the disease field of the varieties, the four-round centralized collection varieties are mainly distributed in disease drugs such as neuropsychiatric drugs, anti-infective drugs, and lipid-lowering drugs.
Among them, lipid-lowering drugs are representatives of the "severe disaster areas" covered by centralized procurement.
In 4+7, the heavyweight lipid-lowering drugs atorvastatin and rosuvastatin were included in the centralized procurement catalog.
The second and third rounds Among them, simvastatin and pitavastatin have also become centralized collections.
So far, all the major varieties of lipid-lowering drugs have been included in the national collection, and the fourth round did not include lipid-lowering drugs.
In the future, more drugs will continue the fate of lipid-lowering drugs and will gradually be covered by centralized procurement.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> As more and more varieties are included in centralized collections, the main disease areas are gradually being eaten by centralized collections.
The sales of centralized collections of lipid-lowering drugs have accounted for 80%.
Among the non-centralized collections of lipid-lowering drugs, there is currently no consensus.
This may be because these varieties have low clinical potential, low sales, and companies lack motivation to make consistent evaluations.
The sales of antacids and anti-asthma + COPD products in the fourth round of centralized procurement accounted for a relatively high proportion of more than 15%.
The two fields of cerebrovascular and peripheral vascular therapeutic agents and immune enhancers are currently not included in the collection of varieties.
For disease fields with different degrees of encroachment by centralized harvesting, companies have different opportunities to enter.
If centralized harvesting varieties account for a relatively high proportion, non-centralized harvesting differentiated varieties are a good choice for the company's layout.

As more and more varieties are included in centralized collections, the main disease areas are gradually being eaten by centralized collections.
The sales of centralized collections of lipid-lowering drugs have accounted for 80%.
Among the non-centralized collections of lipid-lowering drugs, there is currently no consensus.
This may be because these varieties have low clinical potential, low sales, and companies lack motivation to make consistent evaluations.
The sales of antacids and anti-asthma + COPD products in the fourth round of centralized procurement accounted for a relatively high proportion of more than 15%.
The two fields of cerebrovascular and peripheral vascular therapeutic agents and immune enhancers are currently not included in the collection of varieties.
For disease fields with different degrees of encroachment by centralized harvesting, companies have different opportunities to enter.
If centralized harvesting varieties account for a relatively high proportion, non-centralized harvesting differentiated varieties are a good choice for the company's layout.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> 4.
The enthusiasm of the original research pharmaceutical companies to participate has decreased, and TOP domestic pharmaceutical companies have become the main winners

4.
The enthusiasm of the original research pharmaceutical companies to participate is reduced, and the TOP domestic-funded pharmaceutical companies become the main winners.
4.
The original research pharmaceutical companies are less active in participating and the TOP domestic-funded pharmaceutical companies become the main winners.

544px;white-space:normal;background-color:#FFFFFF;line-height:2em;text-align:center;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> The large price drop has greatly reduced the company's sales.
Therefore, starting from the third round of centralized procurement, more MNCs began to give up participating in centralized procurement by reporting high prices and moved to the out-of-hospital market.
In the fourth round of centralized procurement, only two varieties were awarded by the original MNC manufacturers, namely Sanofi’s amisulpride tablets and Fresenius Kabi’s propofol medium/long-chain fat emulsion injections.

The large price drop has greatly reduced the company's sales.
Therefore, starting from the third round of centralized procurement, more MNCs began to give up participating in centralized procurement by reporting high prices and moved to the out-of-hospital market.
In the fourth round of centralized procurement, only two varieties were awarded by the original MNC manufacturers, namely Sanofi’s amisulpride tablets and Fresenius Kabi’s propofol medium/long-chain fat emulsion injections.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> From the perspective of enterprises, winning bids with varieties has become a boost for enterprises to survive in the era of centralized procurement.
After checking the number of TOP5 manufacturers that have won bids in four rounds and five batches of centralized procurement, we found that Zhejiang Huahai performed well in the 4+7 and expansion.
Zhongsheng Pharmaceutical, Qilu, and Yangzijiang were in four rounds and five batches of centralized procurement.
The number of winning bidders is relatively large, all exceeding 20.
It can be seen that TOP domestic-funded pharmaceutical companies are the main winners in centralized procurement.

From the perspective of enterprises, winning bids with varieties has become a boost for enterprises to survive in the era of centralized procurement.
After checking the number of TOP5 manufacturers that have won bids in four rounds and five batches of centralized procurement, we found that Zhejiang Huahai performed well in the 4+7 and expansion.
Zhongsheng Pharmaceutical, Qilu, and Yangzijiang were in four rounds and five batches of centralized procurement.
The number of winning bidders is relatively large, all exceeding 20.
It can be seen that TOP domestic-funded pharmaceutical companies are the main winners in centralized procurement.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> In addition to the number of items to be purchased, the amount of purchase is also an indicator that companies focus on.
The level of purchase amount is not only related to the number of items that have won the bid, but also has a close relationship with the company's quotation strategy.
For example, the big winner of the fourth round of centralized procurement "Garden Pharmaceutical" won the bid for three varieties: doxofylline injection, valsartan and amlodipine tablets and levofloxacin tablets.
Among them, doxofylline injection and valsartan and amlodipine tablets are both the TOP10 varieties in this round of centralized procurement.
Moreover, in the quotations of these varieties, the price of Huayuan Pharmaceutical is relatively high among the bid-winning companies (such as Among the quotations for Sophylline injection, the lowest bid from Yangtze River was 3.
6 yuan/piece, while Huayuan Pharmaceutical’s quotation was 17.
78 yuan/piece), which also ensured that the final purchase amount of Huayuan Pharmaceutical was higher.

In addition to the number of items to be purchased, the amount of purchase is also an indicator that companies focus on.
The level of purchase amount is not only related to the number of items that have won the bid, but also has a close relationship with the company's quotation strategy.
For example, the big winner of the fourth round of centralized procurement "Garden Pharmaceutical" won the bid for three varieties: doxofylline injection, valsartan and amlodipine tablets and levofloxacin tablets.
Among them, doxofylline injection and valsartan and amlodipine tablets are both the TOP10 varieties in this round of centralized procurement.
Moreover, in the quotations of these varieties, the price of Huayuan Pharmaceutical is relatively high among the bid-winning companies (such as Among the quotations for Sophylline injection, the lowest bid from Yangtze River was 3.
6 yuan/piece, while Huayuan Pharmaceutical’s quotation was 17.
78 yuan/piece), which also ensured that the final purchase amount of Huayuan Pharmaceutical was higher.

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> 5.
Future prospects of centralized procurement: 500 varieties are the key, and centralized procurement of Chinese patent medicines for biological medicines is imminent

5.
Future prospects of centralized procurement: 500 varieties are the key, and the centralized procurement of Chinese patent medicines for biological medicines is imminent.
5.
Future prospects of centralized procurement: 500 varieties are the key, and the centralized procurement of Chinese patent medicines for biological medicines is imminent.
5.
Future prospects for centralized procurement: 500 varieties Is the key, the centralized procurement of Chinese patent medicines for biological medicine is imminent

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> Centralized procurement, as one of the most important policies in the new medical reform period, has and will cause violent turbulence in the pharmaceutical industry.
On January 28 this year, the General Office of the State Council issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Pharmaceuticals, State Council Fa [2021] No.
2", which officially normalized and institutionalized centralized procurement.
The document clarifies the scope of selection of centralized procurement products: "The focus is to include drugs with large quantities and high purchase amounts in the basic drug catalogue into the procurement scope, and gradually cover all kinds of clinically necessary and reliable drugs on the domestic market, so that all drugs should be collected.
".

Centralized procurement, as one of the most important policies in the new medical reform period, has and will cause violent turbulence in the pharmaceutical industry.
On January 28 this year, the General Office of the State Council issued the "Opinions on Promoting the Normalized and Institutionalized Development of Centralized and Volume Procurement of Pharmaceuticals, State Council Fa [2021] No.
2", which officially normalized and institutionalized centralized procurement.
The document clarifies the scope of selection of centralized procurement products: "The focus is to include drugs with large quantities and high purchase amounts in the basic drug catalogue into the procurement scope, and gradually cover all kinds of clinically necessary and reliable drugs on the domestic market, so that all drugs should be collected.
".

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> 1“500”，，500。500（），500、、，82。，142+≥3，。500，。

1“500”，，500。500（），500、、，82。，142+≥3，。500，。

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> ，2、。2021，，。，，。，，，。，，，，。

，2、。2021，，。，，。，，，。，，，，。

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'>

544px;text-align:justify;white-space:normal;background-color:#FFFFFF;line-height:2em;box-sizing:border-box ;'> 2020，，2021、、、。、，。，，。

2020，，2021、、、。、，。，，。

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.